TauRx's second-generation tau aggregation inhibitor (TAI), is currently under investigation as a potential disease-modifying treatment for Alzheimer’s disease. Existing symptomatic treatments for Alzheimer’s only transiently address the symptoms and do not slow disease progression. Our drug acts by reducing levels of aggregated or misfolded tau proteins, which are associated with the progressive neurodegeneration that is the hallmark of Alzheimer’s disease.
Our second-generation TAI shares the same active ingredient (methylthioninium [MT]) and mode of action as rember®, TauRx’s first generation TAI. Phase 2 clinical trials of rember® provided the first clinical demonstration that a new therapy targeting protein aggregation could reduce the rate of progression of this deadly disease.
TauRx has now completed two large Phase 3 clinical trials of our lead compound and has started a new clinical trial in mild cognitive impairment, mild, and mild to moderate Alzheimer's, named LUCIDITY. Read a summary of the Phase 3 programme and trial results.